[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2012DN01769A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01769A
IN2012DN01769A IN1769DEN2012A IN2012DN01769A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A IN 1769DEN2012 A IN1769DEN2012 A IN 1769DEN2012A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A
Authority
IN
India
Prior art keywords
antikine
mip
antibodies
lß7ccl4
ccl3
Prior art date
Application number
Inventor
Allison Dan
Raport Carol
Original Assignee
Vlst Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlst Corp filed Critical Vlst Corp
Publication of IN2012DN01769A publication Critical patent/IN2012DN01769A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-lα/CCL3, MIP-lß7CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
IN1769DEN2012 2009-08-28 2010-08-27 IN2012DN01769A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23801509P 2009-08-28 2009-08-28
PCT/US2010/047004 WO2011025962A1 (en) 2009-08-28 2010-08-27 Antikine antibodies that bind to multiple cc chemokines

Publications (1)

Publication Number Publication Date
IN2012DN01769A true IN2012DN01769A (en) 2015-06-05

Family

ID=43628404

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1769DEN2012 IN2012DN01769A (en) 2009-08-28 2010-08-27

Country Status (18)

Country Link
US (3) US8313747B2 (en)
EP (1) EP2470671B1 (en)
JP (2) JP6109571B2 (en)
KR (1) KR101778813B1 (en)
CN (1) CN102782148B (en)
AU (1) AU2010286516B2 (en)
BR (1) BR112012004387A2 (en)
CA (1) CA2771781C (en)
DK (1) DK2470671T3 (en)
ES (1) ES2531561T3 (en)
HR (1) HRP20150162T1 (en)
IN (1) IN2012DN01769A (en)
MX (1) MX2012002427A (en)
PL (1) PL2470671T3 (en)
PT (1) PT2470671E (en)
SI (1) SI2470671T1 (en)
SM (1) SMT201500011B (en)
WO (1) WO2011025962A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2470671T3 (en) * 2009-08-28 2015-02-09 Regeneron Pharma ANTIKIN- ANTIBODIES BINDING TO MULTIPLE CC chemokines
EP3693041A1 (en) * 2011-06-13 2020-08-12 TLA Targeted Immunotherapies AB Treating cancer
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
KR102134088B1 (en) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TWI612059B (en) * 2013-03-15 2018-01-21 美國禮來大藥廠 Pan-elr+ cxc chemokine antibodies
AU2014268316B2 (en) * 2013-05-23 2019-10-10 Takeda Pharmaceutical Company Limited Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
JP6220222B2 (en) * 2013-10-28 2017-10-25 シスメックス株式会社 Method, system and computer program product for assisting diagnosis of rheumatoid arthritis
BR112016013109B1 (en) * 2013-12-09 2021-05-11 Allakos Inc. anti-siglec-8 antibody, nucleic acid, vector, host cell, pharmaceutical composition, its production method and its uses
CA2939931A1 (en) 2014-02-28 2015-09-03 Christopher Robert Bebbington Methods and compositions for treating siglec-8 associated diseases
CN106103479B (en) * 2014-03-04 2019-12-24 彻莫马布有限公司 Anti-eotaxin-2 antibodies recognizing other CCR 3-binding chemokines
CN104198727A (en) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 Human serum CCL2 enzyme-linked immunosorbent assay kit as well as preparation and use methods thereof
TWI576112B (en) * 2014-10-24 2017-04-01 國立陽明大學 Use of mip-1β inhibitor in protecting pancreatic islet and inhibiting the elevation of blood sugar level in diabetes mellitus
MX2017007636A (en) 2014-12-09 2018-03-28 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 274 gene.
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California Cancer treatment combinations
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018159787A1 (en) * 2017-03-01 2018-09-07 国立大学法人北海道大学 Production method for disease model non-human animal, disease model non-human animal, drug screening method using disease model non-human animal, and disease risk determination method
AU2018248672B2 (en) * 2017-04-05 2021-09-30 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
CN110831628A (en) 2017-05-05 2020-02-21 爱乐科斯公司 Methods and compositions for treating allergic eye diseases
WO2019037067A1 (en) * 2017-08-25 2019-02-28 法玛科技顾问股份有限公司 APPLICATION OF MACROPHAGE INFLAMMATORY PROTEIN-1β (MIP-1β) INHIBITOR IN TREATMENT AND CONTROL OF ATHEROSCLEROSIS
WO2019075472A1 (en) * 2017-10-13 2019-04-18 A&G Pharmaceutical, Inc. Monoclonal antibodies and conjugates against prostaglandin f2 receptor inhibitor and uses thereof
JP2021509120A (en) * 2017-12-28 2021-03-18 アスチュート メディカル，インコーポレイテッド Antibodies and assays for CCL14
WO2019165397A1 (en) * 2018-02-26 2019-08-29 Cornell University Quantitative biomarkers of ehv-1 susceptibility and protection
EP3791187A4 (en) 2018-05-11 2022-01-12 Halcyon Therapeutics, Inc. Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN110117329B (en) * 2019-04-03 2020-12-08 河北浓孚雨生物科技有限公司 Fusion polypeptides comprising chemokines and binding partners and uses thereof
WO2021003284A1 (en) * 2019-07-02 2021-01-07 Astute Medical, Inc Antibodies and assays for ccl14
KR102489282B1 (en) * 2019-07-02 2023-01-17 고려대학교 산학협력단 Composition comprising C-C motif chemokine ligand 4, 5, 20, 21 for improving pregnancy
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN113893331A (en) * 2020-07-06 2022-01-07 中国农业科学院特产研究所 Product for inducing female deer to grow antler, preparation method thereof, method for inducing female deer to grow antler and application thereof
WO2022011110A2 (en) * 2020-07-08 2022-01-13 Georgia Tech Research Corporation Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
MX2023004349A (en) * 2020-10-16 2023-08-22 Lanova Medicines Ltd Anti-ccr8 monoclonal antibodies and uses thereof.
CN115598111A (en) * 2021-07-08 2023-01-13 南京大学（Cn） Specific hybridoma cell chemiluminescence screening method based on ortho-position induced immunoassay
CN114990073A (en) * 2022-05-27 2022-09-02 河南农业大学 Monoclonal antibody for resisting porcine CCL2 protein, and preparation method and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
RS20050834A (en) 2002-08-19 2007-12-31 Abgenix Inc., Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
EP1567555A4 (en) 2002-11-27 2006-06-21 Biogen Idec Inc Humanized antibodies against monocyte chemotactic proteins
AU2005318173B2 (en) * 2004-12-21 2011-05-12 Merck Serono Sa CC-chemokine antagonists
CA2695237A1 (en) * 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
DK2470671T3 (en) * 2009-08-28 2015-02-09 Regeneron Pharma ANTIKIN- ANTIBODIES BINDING TO MULTIPLE CC chemokines

Also Published As

Publication number Publication date
BR112012004387A2 (en) 2015-09-08
EP2470671A4 (en) 2013-04-03
AU2010286516A2 (en) 2012-06-14
PL2470671T3 (en) 2015-05-29
PT2470671E (en) 2015-02-05
JP2016135783A (en) 2016-07-28
KR101778813B1 (en) 2017-09-14
KR20120091013A (en) 2012-08-17
EP2470671B1 (en) 2014-12-24
US20130108640A1 (en) 2013-05-02
US8313747B2 (en) 2012-11-20
ES2531561T3 (en) 2015-03-17
US9005617B2 (en) 2015-04-14
SI2470671T1 (en) 2015-04-30
WO2011025962A1 (en) 2011-03-03
EP2470671A1 (en) 2012-07-04
JP2013503192A (en) 2013-01-31
JP6109571B2 (en) 2017-04-05
SMT201500011B (en) 2015-03-05
CA2771781C (en) 2019-01-15
US20150166647A1 (en) 2015-06-18
AU2010286516A1 (en) 2012-03-08
US20110059107A1 (en) 2011-03-10
CN102782148A (en) 2012-11-14
MX2012002427A (en) 2012-08-03
CN102782148B (en) 2016-04-20
CA2771781A1 (en) 2011-03-03
RU2012111820A (en) 2013-10-10
AU2010286516B2 (en) 2016-10-06
HRP20150162T1 (en) 2015-05-08
DK2470671T3 (en) 2015-02-09

Similar Documents

Publication Publication Date Title
IN2012DN01769A (en)
MX353144B (en) Heterodimeric antibody fc-containing proteins and methods for production thereof.
AR096713A1 (en) PURIFICATION PROCESS FOR MONOCLONAL ANTIBODIES
AU2018200640B2 (en) Humanization of rabbit antibodies using a universal antibody framework
CO2019001246A2 (en) Anti-PD-1 antibodies, a production method and a method for its use
MX2010007935A (en) Humanized anti-human nkg2a monoclonal antibody.
TN2014000107A1 (en) Anti-aplhabetatcr antibody
WO2010039900A3 (en) Non-human mammals for the production of chimeric antibodies
DE602006006200D1 (en) ANTIBODY AGAINST 25-HYDROXYVITAMINE D
MX2012000841A (en) Optimizing the production of antibodies.
MX2019015021A (en) Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies.
MX2011003855A (en) Methods for producing antibodies from plasma cells.
MX2013003182A (en) Purification of antibodies using simulated moving bed chromatography.
MX337684B (en) Cross-reactive and bispecific anti-el 17a/f antibodies.
MX2012002458A (en) Humanized anti-cdcp1 antibodies.
MX2009008608A (en) Monoclonal anti-cxcl13 antibodies.
NZ594339A (en) Anti-fgfr3 antibodies and methods using same
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
MX337203B (en) Novel jnk inhibitor molecules.
MX2015011781A (en) Cell culture media and methods of antibody production.
EA201290360A1 (en) HUMANIZED ANTIBODIES AGAINST HUMAN IL-22RA
MX2015010428A (en) Highly galactosylated anti-her2 antibodies and uses thereof.
MX2021014973A (en) High affinity anti-cd3 antibodies, and methods for their generation and use.
PL2099812T3 (en) Manufacturing method of tagatose using galactose isomerization of high yield
EP3897723A4 (en) Production of monoclonal antibody specific to cell receptor cd24